Kalmansohn RB , Kalmansohn RW, Schiff DL: Present status of HMG reductase inhibitors in treatment of dyslipidemiaAngiology49:801-805, 1998.
2.
Kalmansohn RB : The optimum treatment of atherosclerosis : Follow-up of the Angelo May Lecture IThe Forty-Seventh Annual World Assembly, American College of Angiology, Orlando, Florida, October 29, 2000.
3.
Pekkanen J., Linn S., Heiss G., et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular diseaseN Engl J Med322:1700-17171990.
4.
Shepherd J., Cobbe SM, Ford I., et al, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med333:1301-1307, 1995.
5.
Downs J., Clearfield M., Weis S., et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levelsJAMA279:1615-1622, 1998.
6.
Gotto A., Whitney E., Stein E., et al: Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Eur Heart J21:1627-1633, 2000.
7.
Gotto A.: Insights on treating an over-the-counter-type subgroup: Data from the Air Force/Texas Coronary Atherosclerosis Prevention Study PopulationAm J Cardiol85:8E-14E, 2000.
8.
The impending global epidemic of cardiovascular diseasesEur Heart J21:880-883, 2000.
